Rheumatology

Rising Costs Explain Why Canada Is Switching to Biosimilars

June 15th 2020

By Skylar Jeremias

Following in the footsteps of British Columbia, other Canadian provinces are working to implement their own biosimilars initiatives that would switch patients from some of the most costly reference biologics to biosimilar counterparts.

Celltrion's Infliximab Demonstrates Value in Trio of Studies

June 15th 2020

By Tony Hagen

Article

The infliximab biosimilar CT-P13 delivered positive results in studies presented at the European League Against Rheumatism's European E-Congress of Rheumatology 2020.

Celltrion Drug Is Tested in COVID-19 CATALYST Trial

June 11th 2020

By Skylar Jeremias

Article

In search of effective treatments for patients hospitalized with coronavirus disease 2019 (COVID-19), investigators will test an infliximab biosimilar (Remsima, CT-P13). They believe it may help to control cytokine release syndrome, which is associated with COVID-19.

Mylan, Lupin Receive European Approval for Etanercept Biosimilar

June 5th 2020

By Skylar Jeremias

Article

Mylan and Lupin have received market authorization for their etanercept biosimilar (Nepexto, YLB113) in Europe for all indications of the reference product.

Clinically Meaningful Differences Under the Microscope

June 3rd 2020

By Skylar Jeremias

Article

Clinical trials leading up to biosimilar approval may not reveal the full safety and efficacy profile of biosimilars vs reference products, and postmarketing studies may be essential to elucidate any differences, investigators said.

Rituximab Biosimilar Demonstrates Similarity in ASCO Study

May 31st 2020

By Tony Hagen

Article

The rituximab biosimilar candidate ABP 798 met primary and secondary end points for safety, efficacy, and immunogenicity in a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

Fresenius Kabi Chips Away at Neulasta Market in Germany

May 28th 2020

By Tony Hagen

Article

Fresenius Kabi has tapped pharmaceuticals distribution company medac to amplify sales of its pegfilgrastim biosimilar in Germany.

Daewon Pharmaceutical Launches Terrosa in Republic of Korea

May 26th 2020

By Skylar Jeremias

Article

Daewon Pharmaceutical has launched Terrosa, a teriparatide biosimilar, on the Republic of Korea market, after signing a domestic sales agreement with Richter-Helm Biotec. The drug is intended for the treatment of osteoporosis.

Tufts Study: Most Payers Don't Give Preference to Biosimilars

May 21st 2020

By Tony Hagen

Article

A study of coverage decisions by some of the nation’s largest payers indicates biosimilars get preferred status just 14% of the time.

Fresenius Kabi Pegfilgrastim Shows Matching Safety, Immunogenicity

May 21st 2020

By Deana Ferreri, PhD

Article

Fresenius Kabi’s pegfilgrastim biosimilar candidate has demonstrated a similar safety and immunogenicity profile to the reference product (Neulasta).